Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists
Diabetes, Obesity and Metabolism · 2026-06 · 28 (6) · 4546-4558
DOI: 10.1111/dom.70713 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 26.03.2026. Verfasst von Ermeena Shah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Koc University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Weight Gain, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual incretin therapies produce substantial weight loss and cardiometabolic improvement, yet treatment discontinuation is common and associated with adverse metabolic consequences.
Aims
This review aims to synthesize current mechanistic and clinical evidence on metabolic trajectories following GLP‐1RA discontinuation, identify predictors of relapse, and propose a multidisciplinary framework for post‐treatment management. Materials and Methods We conducted a narrative review of evidence from randomized withdrawal trials (including STEP‐1 extension, STEP‐4, and SURMOUNT‐4), systematic reviews, meta‐analyses, and large real‐world observational cohorts encompassing over 289,000 patients.
Results
Discontinuation is associated with substantial weight regain (60%–90% within one year) and parallel reversal of cardiometabolic benefits. Modelling studies suggest that glycaemic, blood pressure, and lipid parameters return to baseline within approximately 12 months, while HbA1c normalizes within 12–18 months. Early discontinuation (< 1 year) is associated with increased risks of coronary artery disease and heart failure compared with continued therapy.
Discussion
Weight recurrence reflects biological adaptations to weight loss, including reactivation of orexigenic pathways and adaptive thermogenesis. In the absence of validated tapering strategies, structured multidisciplinary transition approaches combining pharmacological, behavioral, and psychological interventions may mitigate post‐discontinuation relapse.
Conclusion
GLP‐1RA discontinuation should be considered a high‐risk clinical transition rather than a treatment endpoint. Structured follow‐up and multidisciplinary management are essential to preserve long‐term cardiometabolic benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
- Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, University, Iasi, Romania.
- Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
ORCID-Profile: Mehmet Kanbay
Zitieren
APA
Shah, E., AlShiab, R., Abdo, A., Ozbek, L., Covic, A., & Kanbay, M. (2026). Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists. Diabetes, Obesity and Metabolism, 28(6), 4546-4558. https://doi.org/10.1111/dom.70713
Vancouver
Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists. Diabetes, Obesity and Metabolism. 2026;28(6):4546-4558. doi:10.1111/dom.70713
BibTeX
@article{Shah2026,
author = {Shah, Ermeena and AlShiab, Rama and Abdo, Anas and Ozbek, Lasin and Covic, Adrian and Kanbay, Mehmet},
title = {Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {6},
pages = {4546--4558},
doi = {10.1111/dom.70713}
}
EUVIMED